RxDoctor Payments Data

Maria del Pilar Cekan, MD

Family Medicine · Tampa, FLNPI 1932101011

Payments from drug & device makers

$17,328in general payments, 2019–2025

Across 680 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • plus $7K from 36 others

What the payments were for

  • Food & beverage$17,03598%
  • Education$2932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,328 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$92,852
Medicare patients
184
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$52,678
XareltoRivaroxaban30$32,563
FarxigaDapagliflozin Propanediol33$28,803
JardianceEmpagliflozin29$22,310
RybelsusSemaglutide11$20,046
ProliaDenosumab11$18,719
Janumet XrSitagliptin Phos/Metformin Hcl18$18,633
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$15,187
EliquisApixaban13$14,405
Synjardy XrEmpagliflozin/Metformin Hcl13$10,610
SynthroidLevothyroxine Sodium63$4,544
DayvigoLemborexant12$3,927
Rosuvastatin Calcium281$3,595
Duloxetine Hcl78$2,120
Valsartan60$2,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,443$72,72558 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,479$32,92042 claims
Johnson & JohnsonXarelto$82$32,56330 claims
AstraZenecaFarxiga$2,627$28,80333 claims
AmgenProlia$1,199$18,71911 claims
MerckJanumet Xr$253$18,63318 claims
PfizerEliquis$700$14,40513 claims
AbbVieSynthroid$2,017$4,54463 claims
Eisai Inc.Dayvigo$169$3,92712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →